Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 1965-1968

  Persons, Diane L ^a,d   Arber, Daniel A ^b   Sosman, Jeff A ^c   Borelli, Kristen A ^a   Slovak, Marilyn L ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

C erbB 2; FISH; Fluorescence in situ hybridization; HER 2 neu; IHC; Immunohistochemistry; Melanoma

Indexed keywords

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CHROMOSOMES, HUMAN, PAIR 17; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; SKIN NEOPLASMS;

EID: 0033890809     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-82 1987.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
4. Borg A, Tandon AK, Sigurdsson H, Clark GM, Femo M, Fuqua AW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990.
5. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification charaterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinoma. J Clin Oncol 15: 2894-2904, 1997.
6. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrinicione C, Edgerton S, Allred C, Norton L, Liu ET: ErbB-2, pS3, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998.
7. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: ErhB-2 and response to doxorubicin in patients with axillary lymph node-postive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998.
8. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Research and Treatment 52: 65-77, 1998.
9. Pegram MD, Lipton A, Hayes DF, Weber BI, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncology 16: 2659-2671, 1998.
10. Goldberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clinical Ther 21: 309-318, 1999.
11. Yu D, Wang SS, Dulski KM, Tsia CM, Nicolson GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266, 1994.
12. Tsugawa K, Fushida S, Yonemura Y: Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology 50: 418-425, 1993.
13. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podartz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179-185, 1992.
14. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN: Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-erbB2 expression in glioblastomas (GBMs). J Neurooncol 16: 93-104, 1993.
15. Easty DJ, Herlyn M, Bennett DC: Abnormal protein tryosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60: 129-136, 1995.
16. Chenevix-Trench G, Martin NG, Ellem KAO: Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53. Oncogene 5: 1187-1193, 1990.
17. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg K-J, Erin K, Macs H, Kono K, Hising C, Peterson M. Larsson O, Lan L, Apella E, Sette A, Celis E, Kiessling R: Identification of new HER2/neu-derived peptide epitopcs that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunology 163: 1037-1044, 1999.
18. Ramachandra S, Gillett CE, Millis RR: A comparative immunohistochemical study of mammary and extramammary Paget's disease and superficial spreading melanoma, with particular emphasis on melanocytic markers. Virchows Arch 429: 371-376, 1996.
19. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-1330, 1997.
20. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72, 1996.
21. Persons DL, Bui MM. Yung J-F, Lowery MC, Mark HFL, Wong EY, Birkmeier JM, Yang SJ, Masood S: Fluorescence in-situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study. Annals Clinical Laboratory Science 30: 41-48, 2000.
22. Sheibani K, Tubbs RR: Enzyme immunohistochemistry: technical aspects. Semin Diagn Pathol 1: 235-250, 1984.
23. Battifora H, Alsabeh R, Jenkins KA, Gown A: Epitope retrieval (unmasking) in immunohistochemistry. Adv Pathol Lab Med 8: 101-118, 1995.
24. Press MF, Hung G, Godolophin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777, 1994.
25. Persons DL, Borelli KA, Hsu P: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using flourescence in situ hybridization. Modern Pathology 10: 720-727, 1997.